Results 1 to 10 of about 18,010 (199)

Pharmacokinetics, safety and population pharmacokinetics/pharmacodynamics analysis of meropenem-vaborbactam in Chinese healthy participants [PDF]

Frontiers in Pharmacology
BackgroundMeropenem-vaborbactam is a fixed-dose β-lactam/β-lactamase inhibitor combination active against carbapenem-resistant Enterobacterales (CRE), especially Klebsiella pneumoniae carbapenemase (KPC)-producing CRE.
Wanzhen Li, Wanzhen Li, Qiong Wei, Mengting Chen, Mengting Chen, Xiaofen Liu, Xiaofen Liu, Beining Guo, Beining Guo, Yuancheng Chen, Qi Zhang, Wei Guan, Long Shen, Xiaohui Wang, Nanyang Li, Yan Chen, Yan Chen, Xin Li, Xin Li, Yingying Hu, Jing Zhang, Jing Zhang, Jing Zhang, Xiaojie Wu, Xiaojie Wu   +24 more
doaj   +5 more sources

Meropenem/Vaborbactam—A Mechanistic Review for Insight into Future Development of Combinational Therapies [PDF]

Antibiotics
Beta-lactam antibiotics have been a major climacteric in medicine for being the first bactericidal compound available for clinical use. They have continually been prescribed since their development in the 1940s, and their application has saved an ...
Woo Shik Shin
exaly   +6 more sources

Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing Klebsiella pneumoniae in the hollow fiber infection model [PDF]

Antimicrobial Agents and Chemotherapy
Meropenem/vaborbactam is a preferred treatment option for KPC-producing Klebsiella pneumoniae (KPC-Kp) infections, but clinical cure rates remain suboptimal when it is used alone.
Nidhi Singh, Christin M. L. Jogan, Yanan Zang, Xindi Shan, Yinzhi Lang, Arunkumar Karunanidhi, Jackson V. Watkins, Brooke N. Curry, Pranita D. Tamma, Sophie H. Nozick, Egon A. Ozer, Alan R. Hauser, Jürgen B. Bulitta, Zackery P. Bulman   +13 more
doaj   +3 more sources

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae [PDF]

Antimicrobial Agents and Chemotherapy
Carbapenem-resistant Enterobacterales (CREs) are recognized as an urgent public threat by the Centers for Disease Control and Prevention. This study assesses the activity of humanized serum concentrations for meropenem (2 g Q8h), meropenem-vaborbactam (4
Thomas Lavoie, Teresa Sierra, Katie Daffinee, Jason M. Pogue, Brahim Achour, Kerry LaPlante   +5 more
doaj   +3 more sources

In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii [PDF]

Scientific Reports
Treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) presents a growing clinical challenge. This study evaluated the in vitro efficacy of eravacycline and the potential synergistic activity of meropenem-vaborbactam in combination with either ...
Amira H. El-Ashry, Ahmed Mostafa Abdrabou, Nora El-Tantawy, Rasha Mahmoud, Rasha El-Mahdy   +4 more
doaj   +4 more sources

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections [PDF]

Antimicrobial Agents and Chemotherapy
Thirty-day mortality was similar in a propensity-score-weighted cohort of 73 patients with KPC-producing Enterobacterales infections treated with ceftazidime-avibactam or meropenem-vaborbactam.
Sara M. Karaba, Dariusz A. Hareza, Jose M. Munita, Jose R. W. Martinez, Yehudit Bergman, Armani M. Hawes, Zackery P. Bulman, Sara E. Cosgrove, Patricia J. Simner, Pranita D. Tamma   +9 more
doaj   +3 more sources

Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam [PDF]

Antimicrobial Agents and Chemotherapy
We report an outbreak of KPC-producing Pseudomonas aeruginosa in Spain, involving four patients and an environmental isolate recovered from a hospital sink.
Gloria Pérez-Rodríguez, Pablo Aja-Macaya, Lucía González-Pinto, Biel Taltavull, María Tarriño-León, María del Mar Gallardo-García, Tania Blanco-Martín, Salud Rodríguez-Pallares, Lucía Sánchez-Peña, Miriam Moscoso, Alejandro Beceiro, Antonio Oliver, Germán Bou, Jorge Arca-Suárez   +13 more
doaj   +3 more sources

Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection. [PDF]

J Pediatr Pharmacol Ther
Meropenem/vaborbactam is a combination antibiotic with a carbapenem and a carbapenemase inhibitor typically reserved for extensively drug-resistant bacterial infections, such as carbapenem-resistant Enterobacterales (CRE). Meropenem/vaborbactam is approved by the United States Food and Drug Administration for use in adults for complicated urinary tract
Sano U, Meyers R, Hasan U, Smoke S.
europepmc   +5 more sources

Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence. [PDF]

Infect Dis Ther
Among drug-resistant bacteria, carbapenem-resistant Enterobacterales (CRE) are a major clinical challenge with limited options for treatment. In the last several years, new treatment options have emerged for CRE, including meropenem-vaborbactam (MVB).
Bassetti M, Giacobbe DR, Vena A, Poulakou G, Rossolini GM, Soriano A, Nicolau DP.   +6 more
europepmc   +8 more sources

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam [PDF]

Infectious Diseases and Therapy, 2020
Plain Language Summary Carbapenem-resistant gram-negative pathogens, specifically, Enterobacteriaceae, remain an urgent public health threat, and safe, effective treatment options are limited. The antibiotic agents meropenem and vaborbactam were selected
Eric Wenzler, Patrick J. Scoble
doaj   +3 more sources